EU fines pharmaceutical giants $22 million


Save Story
Leer en espaƱol

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

AMSTERDAM (AP) - The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.

In a statement, the Commission's antitrust chief, Joaquin Almunia, said the two companies "shockingly deprived patients in the Netherlands, including people suffering from cancer, from access to a cheaper version of this medicine."

The Commission found that after Johnson & Johnson's patent on a patch containing the drug Fentanyl expired in 2005, it paid Novartis to delay launching a generic version. The delay lasted 17 months, and was more profitable for both companies than competing honestly would have been.

J&J's fine was 10.7 million euros ($14.7 million), and Novartis' was 5.5 million euros.

(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Most recent World stories

Related topics

World
KSL.com Beyond Series

KSL Weather Forecast

KSL Weather Forecast
Play button